Business
Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease
Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / May 13, 2021 / Halberd Corporation (OTC PINK:HALB) announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease. This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications. The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences (PAGES) Department. Initial experiments using the laser are intended to calibrate optimum laser wave length and pulse duration exposure. YSU currently has four different lasers available from which to select the best emissive energy power source.The laser is one of two methodologies Halberd has available for the safe but efficacious eradication of targeted antigens. Halberd is also actively testing to determine which approach, laser or radiofrequency, may be the most efficacious with regard to a particular disease. The research involves Halberd's close coordination of two major universities.William A. Hartman, Halberd's Chairman, President & CEO stated, "Laser calibration testing is extremely important in order to establish the minimum power needed to eradicate disease targets from bodily fluids while not harming surrounding biologic materials. Dr. Chen, of GreenBioAZ, uses our patent-pending technology to prepare antibodies by attaching them to metallic nanoparticles. The three essential items (antibody, metallic nanoparticle and antigen) are chemically conjugated into a single moiety which can be destroyed either via radio frequency or laser energy. Concurrently, testing using radio frequency waves as well as lasers on E. coli bacteria in various media, including cerebral spinal fluid and blood, is scheduled to commence shortly."Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer, commented, "Halberd has two very strong patents covering the extra-corporeal process and eight related provisional patent applications filed in just the last six months. The extracorporeal aspect is necessary for the effective application of radio frequency and/or laser emissive energy for the eradication of targeted disease states. We believe Halberd's proprietary technology...